Table 3.

General Linear Model analysis results for Nijmegen Continuity Questionnaire (NCQ) team and cross-boundary continuity (TCC) baseline-to-second follow-up change score.

Model term			Coefficient		95% CI		P value
Treatment
	Intercept	1.1		−0.9 to 3.1		.26
	Group (intervention vs control)	0.1		−0.4 to 0.6		.66
	Cancer type (breast vs prostate)	−0.2		−0.7 to 0.4		.59
	Age (continuous)	0		0 to 0		.52
	Total comorbid conditions (continuous)	0		−0.1 to 0.1		.55
	Baseline NCQ TCC	−0.6		−1.1 to −0.2		.01
	Baseline NCQ PC1a	0.1		−0.2 to 0.4		.41
	Baseline NCQ PC2b	0.3		0 to 0.7		.07
	Intervention × cancer type (interaction)	0.3		−0.5 to 1.1		.49
Survivorship
	Intercept	2.2		0.5 to 4		.01
	Group (intervention vs control)	0		−0.3 to 0.3		.89
	Sex (female vs male)	−1		−1.8 to −0.2		.02
	Cancer type (breast vs colorectal)	0.5		−0.1 to 1.2		.13
	Age (continuous)	0		0 to 0.1		.21
	Total comorbid conditions (continuous)	0.1		0 to 0.1		.14
	Baseline NCQ TCC	−0.6		−0.9 to −0.3		<.001
	Baseline NCQ PC1	0		−0.2 to 0.2		.87
	Baseline NCQ PC2	0.2		−0.1 to 0.4		.20

^aPC1: personal continuity relating to the PCP.

^bPC2: personal continuity relating to the cancer specialist.